Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.
Press releases published on August 25, 2025
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
GlobeNewswire
·
August 25, 2025
US$2,054,651 non-dilutive grant from the US National Cancer Institute to complete manufacturing of Bria-Pros+TM clinical supply and support Phase 1/2a trial in metastatic prostate cancer Expands Bria-OTS+ novel personalized off-the-shelf immunotherapy …
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
GlobeNewswire
·
August 25, 2025
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on …
Spectral Medical Receives US$3 Million From Vantive
GlobeNewswire
·
August 25, 2025
TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million …
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
GlobeNewswire
·
August 25, 2025
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy Company …
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
GlobeNewswire
·
August 25, 2025
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per …
Propanc Biopharma Provides Shareholder Update
GlobeNewswire
·
August 25, 2025
MELBOURNE, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today …
New Report Reveals 85% of Health Plans Have Yet to Centralize Their Data Across Systems
GlobeNewswire
·
August 25, 2025
BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Arcadia® (arcadia.io), a leading healthcare data platform, today announced the publication of its latest research report, Scaling Smarter: The Data Strategies Powering High-Performing Health Plans. The report …
Incyclix Bio Secures $11.25 Million Series B Extension to Advance the Phase 1/2 Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors
GlobeNewswire
·
August 25, 2025
RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today …
EDAP to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
August 25, 2025
AUSTIN, Texas, August 25, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate in a fireside chat and host 1x1 …
Climb Bio to Present at Upcoming September 2025 Investor Conferences
GlobeNewswire
·
August 25, 2025
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in …
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
GlobeNewswire
·
August 25, 2025
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making …
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
GlobeNewswire
·
August 25, 2025
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of Directors Research and Development Committee established to accelerate innovation and long-term growth Dr. Ken Takeshita appointed to the Scientific Advisory Board ROCKVILLE, Md., Aug. …
Jade Biosciences to Participate in Upcoming Conferences
GlobeNewswire
·
August 25, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
GlobeNewswire
·
August 25, 2025
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that …
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
GlobeNewswire
·
August 25, 2025
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines – – Substantial improvement in …
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
GlobeNewswire
·
August 25, 2025
ALACHUA, Fla. and TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License …
Babak Baru Kehidupan Pasien: KFSHRC Mengobati Penyakit Langka Setelah Pengobatan Khusus 22 Tahun
GlobeNewswire
·
August 25, 2025
RIYADH, Arab Saudi, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Dalam sebuah kisah langka tentang ikatan seumur hidup antara seorang pasien dan suatu lembaga kesehatan, King Faisal Specialist Hospital …
KFSHRC, 22년간 이어진 전문 진료로 희귀병 환자 치료 성공
GlobeNewswire
·
August 25, 2025
사우디아라비아 리야드, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 리야드에 위치한 킹 파이살 전문병원 겸 연구센터 (KFSHRC)는 환자와 의료 기관 사이에 평생에 걸친 유대라는 드문 사례를 보여주듯, 한 환자를 영아기부터 지원해 왔으며, 희귀 유전성 혈액 응고 장애에 대해 22년간 지속적인 치료를 제공한 끝에 세계 최초로 이 질환 환자에게 간 이식을 성공적으로 시행하는데 마침내 성공했다. 환자의 생후 몇 개월 무렵 첫 번째 질환 징후가 …
新たに生まれ変わる人生： キング・ファイサル・スペシャリスト病院・研究センター (King Faisal Specialist Hospital & Research Centre、KFSHRC)、22年にわたる専門治療の末に希少疾患を治療
GlobeNewswire
·
August 25, 2025
サウジアラビア、リヤド発, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 患者と医療機関の生涯にわたる絆を示す珍しい例として、リヤドのキング・ファイサル・スペシャリスト病院・研究センター (KFSHRC) は、希少な遺伝性血液凝固障害の患者を乳幼児期から支え続け、22年間にわたり継続的に治療を提供し、最終的にこの特殊な疾患では世界初となる肝臓移植を実現した。 生後数カ月で病気の初期症状が現れたとき、KFSHRCは、患者の病状を安定させるため、奔走した。 …
Transformasi Hidup: KFSHRC Berjaya Rawat Penyakit Jarang Selepas 22 Tahun Penjagaan Rapi
GlobeNewswire
·
August 25, 2025
RIYADH, Arab Saudi, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Dalam satu kisah luar biasa mengenai ikatan seumur hidup antara pesakit dan institusi penjagaan kesihatan, King Faisal Specialist Hospital …